BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/23/2019 8:07:00 AM | Browse: 783 | Download: 897
 |
Received |
|
2019-03-18 05:21 |
|
Peer-Review Started |
|
2019-03-19 09:21 |
|
To Make the First Decision |
|
2019-09-18 01:47 |
|
Return for Revision |
|
2019-09-19 01:49 |
|
Revised |
|
2019-10-26 14:10 |
|
Second Decision |
|
2019-12-05 08:52 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-12-08 23:25 |
|
Articles in Press |
|
2019-12-08 23:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-12-19 09:06 |
|
Publish the Manuscript Online |
|
2019-12-23 08:07 |
| ISSN |
2218-6204 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Minireviews |
| Article Title |
Adult Langerhans cell histiocytosis and immunomodulatory drugs: Review and analysis of thirty-four case reports
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Endri Mauro, Piero Maria Stefani and Filippo Gherlinzoni |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Endri Mauro, PhD, Doctor, Doctor, Internal Medicine, Haematology Unit, Ospedale Cà Foncello, Piazzale Ospedale 1, Treviso 31100, Treviso, Italy. endri76@libero.it |
| Key Words |
Langerhans cell histiocytosis; Immunomodulatory drugs; Thalidomide; Lenalidomide; ; |
| Core Tip |
Langerhans cell histiocytosis (LCH) is a rare neoplastic disease derived from dendritic cells that is seen in children as well as in adults. There is not a standard first-line treatment in adults; no prospective trials have been undertaken on this population, and chemotherapy schedules are often reported from pediatric experiences with suboptimal efficacy and a higher toxicity in adults than in children. Immunomodulatory drugs (IMiDs), as less toxic therapeutic options, have been considered for treating LCH. We analyzed the efficacy and safety of IMiDs in adults with LCH from previously published research. |
| Publish Date |
2019-12-23 08:07 |
| Citation |
Mauro E, Stefani PM, Gherlinzoni F. Adult Langerhans cell histiocytosis and immunomodulatory drugs: Review and analysis of thirty-four case reports. World J Hematol 2019; 8(1): 1-9 |
| URL |
https://www.wjgnet.com/2218-6204/full/v8/i1/1.htm |
| DOI |
https://dx.doi.org/10.5315/wjh.v8.i1.1 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
